Browse News
Filter News
Found 43 articles
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
4/11/2024
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference.
-
Mainz Biomed Provides Year-End Corporate Review 2023
1/9/2024
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced a year end summary of its corporate and product development progress.
-
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
8/15/2023
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the results of the first six months and second quarter ending June 30, 2023 and provided a corporate update.
-
First Distribution Agreement Executed with Sonic Healthcare
7/5/2023
Microba Life Sciences Limited is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia.
-
Microba Commences Phase I Clinical Trial for IBD Therapeutic
6/28/2023
Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease.
-
Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/16/2023
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced first quarter results which ended March 31, 2023 and provided a corporate update.
-
Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert
5/10/2023
Mainz Biomed N.V. announced a research collaboration with Microba Life Sciences, a precision microbiome company leveraging a world-leading technology platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases.
-
Bacthera Joins Microbiome Therapeutics Innovation Group
4/24/2023
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bacthera to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference - April 19, 2023
4/19/2023
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment.
-
Microba Launches Next Generation Healthcare Testing
2/28/2023
Microba Life Sciences Limited, a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.
-
Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners
1/6/2023
Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced the opening of Bioworks7, the latest expansion of its biological engineering foundry.
-
Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership
11/29/2022
Microba Life Sciences Limited is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba.
-
SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME
10/27/2022
SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.
-
Ginkgo Bioworks Appoints Dr. Behzad Mahdavi as Senior Vice President of Biopharma Manufacturing & Life Science Tools
9/1/2022
Ginkgo Bioworks, the leading horizontal platform for cell programming, announced that Behzad Mahdavi, Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools.
-
Microba Accelerates Cancer Program With New Leads
5/5/2022
Microba Life Sciences Limited is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics
4/4/2022
Microba Life Sciences, a precision microbiome science company, and Ginkgo Bioworks, the leading horizontal platform for cell programming, announced a partnership to identify single-strain, live bacteria product candidates against autoimmune diseases.
-
Arc Bio Joins Microbiome Therapeutics Innovation Group
2/9/2022
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Arc Bio to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.
-
Microba to Present Therapeutic Discovery Progress at Microbiome Movement – Drug Development Summit
1/25/2022
Microba Life Sciences, a precision microbiome science company, will showcase its Therapeutic Platform and Discovery Platform for the identification of novel microbial signatures at annual Europe summit.
-
Research into gut microbiome-autism link reveals new perspective in collaborative Austism CRC study
11/12/2021
Results published in Cell, led by Mater Research and The University of Queensland, show that dietary restriction drives microbiome diversity changes in autistic individuals.